CN106822205A - Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition - Google Patents
Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition Download PDFInfo
- Publication number
- CN106822205A CN106822205A CN201710231281.5A CN201710231281A CN106822205A CN 106822205 A CN106822205 A CN 106822205A CN 201710231281 A CN201710231281 A CN 201710231281A CN 106822205 A CN106822205 A CN 106822205A
- Authority
- CN
- China
- Prior art keywords
- panax japonicus
- conopsea extraction
- treatment
- extract
- kidney fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition, belongs to technical field of pharmaceuticals.Panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V in ring conopsea extraction have preferable therapeutic effect to improving and treating kidney fibrosis, can be applied to prepare the medicine for the treatment of kidney fibrosis.Present invention also offers a kind of composition with above-mentioned ring conopsea extraction, said composition can be used in improving and treating kidney fibrosis.
Description
Technical field
The present invention relates to technical field of pharmaceuticals, and more particularly to a kind of ring conopsea extraction is preparing treatment kidney fibrosis medicine
The application of thing and composition.
Background technology
Kidney fibrosis (renal fibrosis) include kidney region fibrosis and glomerulosclerosis, are the functions of kidney by being good for
To damage, then to damage, until the progressive process that function is lost, kidney fibrosis are almost all of primary or Secondary cases kidney to health
Dirty disease develops into the co-channel of End-stage renal failure, its be the main Pathological of various chronic renal diseases it
One.The mechanism of kidney fibrosis is complex, celliferous propagation is mainly produced with extracellular matrix-cell and activation, blood vessel are lived
Property material, cell factor and extracellular matrix shift equilibrium are relevant.Numerous studies show that kidney fibrosis compare primary glomerular
Disease is easier to cause the progressive of renal function to deteriorate.Therefore, effective treatment method and medicine are actively found to kidney fibrosis
Process is intervened, with very great meaning.
Existing kidney fibrosis medicine includes western medical treatment and the class of Chinese traditional treatment two, and the former mainly uses chemicals
Treatment, such as pirfenidone, relaxain, HGF, bone morphogenetic protein, the suppression of glutaryl CoA-reductase
The medicines such as preparation, ACEI and angiotensin receptor antagonist, these medicines mostly have larger
Side effect；The latter mainly strengthens using with clearing heat and detoxicating, promoting blood circulation and removing blood stasis, eliminating the phlegm dehumidifying, softening and resolving hard mass, help healthy tendency, enriching yin
The square medicine of positive the effects such as, such as rheum officinale, the red sage root, pseudo-ginseng, peach kernel, curcuma zedoary, safflower, Cordyceps sinensis, traditional Chinese medicine is in fiber in recent years
Change treatment aspect and achieve huge progress.
Panax japonicus is the dry rhizome of Araliaceae panax japonicus (Panax japonicus C.A.Mey.), and it has taste
Reinforcement body, promoting blood circulation and removing blood stasis, blood stasis removing analgesic, effect of hemostasis eliminating the phlegm, are described as " king of herbal medicine " in the Tujia and Miao nationalities compact community, belong to
Rare " seven classes " Chinese herbal medicine of Precious, Rare, Endangered.Research shows that ring conopsea extraction has functions that anti-inflammatory, antitumor, reducing blood lipid,
There is effective therapeutic effect to various diseases, such as ring conopsea extraction can be used in preventing and treating COPD
Disease, protect liver, reducing blood lipid, intestinal mucosal injury is treated, antithrombotic reagent is prepared, is prepared anti-urarthritis medicine, prepares anti-bone
Loose medicine of matter etc., but application of the ring conopsea extraction in terms of the medicine for the treatment of kidney fibrosis is prepared is there is no at present.
The content of the invention
The application for the treatment of kidney fibrosis medicine is being prepared it is an object of the invention to provide a kind of ring conopsea extraction.
Another object of the present invention is to provide a kind of composition, said composition has for improving and treating kidney fibrosis
Preferable effect.
The present invention is solved its technical problem and is realized using following technical scheme.
A kind of ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine, and it is many that ring conopsea extraction includes panax japonicus
At least one in sugar extract or panax japonicus total saponins extract.
Further, in present pre-ferred embodiments, ring conopsea extraction includes that mass ratio is 1：4.5~6 ring
Gracilis polysaccharide extract and panax japonicus total saponins extract.
Further, in present pre-ferred embodiments, ring conopsea extraction includes that mass ratio is 1：5~5.5 ring
Gracilis polysaccharide extract and panax japonicus total saponins extract.
Further, in present pre-ferred embodiments, ring conopsea extraction is panax japonicus polysaccharides extract, its unit bodies
Reuse amount is daily 30~450mg/kg.
Further, in present pre-ferred embodiments, ring conopsea extraction is panax japonicus total saponins extract, its unit
Body weight consumption is daily 40~520mg/kg.
Further, in present pre-ferred embodiments, the content of panax japonicus saponin V is in panax japonicus total saponins extract
50~75%.
Further, in present pre-ferred embodiments, panax japonicus polysaccharides extract is obtained according to following preparation method：
To the water that 5~7 times of its quality is added in panax japonicus powder, immersion is decocted 1~2 hour after 1~3 hour, filtering；After filtering
Filter residue carries out 2~3 second extractions and filters；Merge the filtrate after all filterings, be concentrated under reduced pressure to give concentrate, to concentrate
Carry out 2~3 alcohol extractings；Merge the sediment that all alcohol extractings are obtained, freeze-drying.
Further, in present pre-ferred embodiments, the method for second extraction is：To adding its quality 3~5 in filter residue
Times water, then stirred with the speed of 350~450r/min and filtered after decocting 1~2 hour.
Further, in present pre-ferred embodiments, panax japonicus total saponins extract is according to following preparation method system
：To the ethanol that 9~12 times of its quality is added in panax japonicus powder, simultaneously refluxing extraction 1~3 is small for water-bath after soaking 2~4 hours
When, filtering；2~3 times are carried out to the residue after filtering to extract again and filter, merge the extract solution after all filterings, be recovered under reduced pressure
Solid is configured to after ethanol：Liquid is 1g：The solution of 3~5mL, water, mass concentration are used using HP-400 macroporous resin columns successively
60% ethanol elution solution obtains ethanol eluate, by ethanol eluate freeze-drying.
Present invention also offers a kind of composition, it includes above-mentioned ring conopsea extraction and medical accessory.
The beneficial effects of the invention are as follows：Answering for treatment kidney fibrosis medicine is being prepared the invention provides ring conopsea extraction
With showing panax japonicus polysaccharides in ring conopsea extraction, panax japonicus total saponins and panax japonicus saponin V for improving and treatment kidney is fine
Dimensionization has significant curative effect, and its prospect for having exploitation and preparing treatment kidney fibrosis medicine, ring conopsea extraction also has
To human body Small side effects, the advantage of safety is used.Present invention also offers a kind of composition comprising above-mentioned ring conopsea extraction,
Said composition can be used in improving and treating kidney fibrosis.
Specific embodiment
To make the purpose, technical scheme and advantage of the embodiment of the present invention clearer, below will be in the embodiment of the present invention
Technical scheme be clearly and completely described.Unreceipted actual conditions person, builds according to normal condition or manufacturer in embodiment
The condition of view is carried out.Agents useful for same or the unreceipted production firm person of instrument, are the conventional product that can be obtained by commercially available purchase
Product.
Prepared by the application for the treatment of kidney fibrosis medicine and group to ring conopsea extraction provided in an embodiment of the present invention below
Compound is specifically described.
The embodiment of the invention provides a kind of ring conopsea extraction and prepare the application for the treatment of kidney fibrosis medicine, the ring
Contain at least one in panax japonicus polysaccharides extract, panax japonicus total saponins extract or panax japonicus saponin V in conopsea extraction；And
When ring conopsea extraction is panax japonicus polysaccharides extract, its per weight consumption is daily 30~450mg/kg；Work as panax japonicus
When extract is panax japonicus total saponins extract, its per weight consumption is daily 40~520mg/kg；When ring conopsea extraction
For panax japonicus polysaccharides extract and panax japonicus total saponins extract mixture when, panax japonicus polysaccharides extract and panax japonicus total soap
The mass ratio of glucoside extract is 1：4.5~6；And when the mass ratio of panax japonicus polysaccharides extract and panax japonicus total saponins extract is
1：When 5~5.5, ring conopsea extraction has optimal therapeutic effect for improving kidney fibrosis symptom；Panax japonicus polysaccharides are extracted
The preferred unit body weight consumption of thing is daily 30~120mg/kg, and the preferred unit body weight consumption of panax japonicus total saponins extract is
Daily 40~150mg/kg；The content of panax japonicus saponin V is preferably 50~75%, panax japonicus soap in panax japonicus total saponins extract
The purity of glycosides V is more than 90%.
Wherein, panax japonicus polysaccharides extract is obtained according to following preparation method：To adding its quality 5 in panax japonicus powder
~7 times of water, immersion is decocted 1~2 hour after 1~3 hour, filtering；2~3 second extractions are carried out to the filter residue after filtering simultaneously
Filtering；The method of second extraction is：To the water that 3~5 times of its quality is added in filter residue, then with the speed of 350~450r/min
Filtered after stirring and decoct 1~2 hour；Merge the filtrate after all filterings, be concentrated under reduced pressure to give concentrate, concentrate is carried out
2~3 alcohol extractings；Alcohol extracting be in concentrate add ethanol to ethanol mass concentration be 60~65%, and place more than 12 hours
Filtering afterwards obtains sediment；Merge the sediment that all alcohol extractings are obtained, freeze-drying obtains panax japonicus polysaccharides extract.
Panax japonicus total saponins extract is obtained according to following preparation method：To added in panax japonicus powder its quality 9~
Water-bath and refluxing extraction 1~3 hour, filtering after 12 times of ethanol, immersion 2~4 hours；Residue after filtering is carried out 2~3 times
Extract again and filter, then it is ethanol and refluxing extraction 2~3 times to 4~6 times of its quality is added in residue to extract, and is extracted every time
Obtain extract solution within 1.5~2 hours：During refluxing extraction, using ultrasonication residue, the frequency of ultrasonication is
26~28KHz, power was 600~900KW, at interval of ultrasonication after 30~45 seconds 10~20 seconds；After merging all filterings
Extract solution, be configured to solid after ethanol is recovered under reduced pressure：Liquid is 1g：The solution of 3~5mL, uses HP-400 macroporous resin columns
Ethanol eluate is obtained with the ethanol elution solution of water, mass concentration 60% successively, ethanol eluate freeze-drying is obtained into bamboo
Section ginseng total saponin extracts.
Present invention also offers a kind of composition, it includes above-mentioned ring conopsea extraction and medical accessory, and said composition can
Used as common drugs such as tablet, granule, capsule, paste with preparing.
1. experiment material.
Extraction, purifying and the preparation of 1.1 panax japonicus polysaccharides.
Panax japonicus is worn into less than 100 μm of powder, to the water that 5 times of its quality is added in panax japonicus powder, is soaked 3 hours
Decoct 2 hours afterwards, be filtrated to get filtrate and filter residue, 2 second extractions are carried out to filter residue and obtains filtrate, the method for second extraction
It is：To the water that 4 times of its quality is added in filter residue, then stirred with the speed of 420r/min and filtered after decocting 1.5 hours；Merge
Filtrate Hou Minus pressures are concentrated to give concentrate, 3 alcohol extractings are carried out to concentrate and is precipitated thing, and alcohol extracting is to adding second in concentrate
Alcohol to concentration of alcohol be 65%, and place 18 hours after filter obtain sediment, merge sediment after freeze-drying obtain ring
Gracilis polysaccharide extract.
Extraction, purifying and the preparation of 1.2 panax japonicus total saponins.
Panax japonicus is worn into less than 200 μm of powder, to the ethanol that 9 times of its quality is added in panax japonicus powder, immersion 3 is small
When after water-bath refluxing extraction 2 hours, be filtrated to get extract solution and residue, carry out 2 times to residue and extract again to obtain extract solution, then carry
Take is obtained extract solution 3 times, extracts 2 hours every time, in refluxing extraction to adding the alcohol reflux of 5 times of its quality to extract in residue
During, using ultrasonication residue, the frequency of ultrasonication is 28KHz, and power is 600KW, after 30 seconds
Ultrasonication 12 seconds；Merge after extract solution , Minus push back receipts ethanol and be configured to solid：Liquid is 1g：The solution of 4.5mL, uses
HP-400 macroporous resin columns obtain ethanol eluate with water, 60% ethanol elution solution successively, ethanol eluate is dry
To panax japonicus total saponins extract.
Extraction, purifying and the preparation of 1.3 panax japonicus saponin V.
Taking above-mentioned panax japonicus total saponins purifies HP-20 resin columns, and the ethanol eluate , Minus for collecting 55~85% push back receipts
Ethanol freeze-drying, obtains panax japonicus saponin V, and its purity is 95%.
2. panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V improve the experimental study with treatment kidney fibrosis.
2 experimental techniques and content.
2.1 animals.
Healthy male Wistar rat 90, purchased from Hubei Province Animal Experimental Study center, body weight 150-200g.Experiment is big
Mouse is placed in cleaning grade laminar-flow rack and raises, and free water and ingests, and daily lighting hours is 12h (7：00-19：00), environment
Temperature is 23 ± 2 DEG C, and relative humidity is 75 ± 10%.
2.2 main agents and equipment.
Benazepil (Novartis Pharma AG)；Hydroxyproline (HYP) kit (build up bioengineering and grind by Nanjing
Study carefully institute)；Fibronectin (FN) kit (Shanghai institute of Biological Products)；(Wuhan Xinghe reaches the limited public affairs of commerce and trade to ethanol disinfection liquid
Department)；Disinfectant tamed iodine (Hubei Rui Kang Pharmaceutical Technology Co., Ltd)；Chloraldurate (Chemical Reagent Co., Ltd., Sinopharm Group)；
Sodium chloride injection (Binghu Shuanghe Pharmaceutical Co., Ltd., Wuhan)；Formalin (the limited public affairs of Chinese medicines group chemical reagent
Department)；Sodium cellulose glycolate (CMC-Na) (Chemical Reagent Co., Ltd., Sinopharm Group)；Common mouse feed；Thermostat water bath (on
Hai Yarong biochemical instruments factory)；Satrious electronic balances (Germany)；ELIASA (Thermo Fisher scientific)；It is low
Warm supercentrifuge (day U.S. Z323K)；LXJ-II centrifuges (Shanghai medical analytical instrument factory)；SHB-3A circulating water types are multiplex true
Empty pump；Liquid-transfering gun (big dragon Medical Devices (Shanghai) company).Microscope (Motic SFC-28SERIES).
2.3 solution are prepared.
2.3.1 the preparation of 0.4%CMC-Na solution：Precision weighs 4gCMC-Na and is dissolved in 1000mL distilled water, is configured to
Concentration is 0.4% CMC-Na solution.
2.3.2 prepared by positive control solution：Weigh benazepil piece appropriate, be placed in and fine powder is ground into mortar, be dissolved in appropriate
In CMC-Na solution, the benazepil suspension of 1mg/mL is obtained, be positive control liquid.
2.3.3 the preparation of DT (panax japonicus polysaccharides) liquid：Precision weighs DT in right amount, is dissolved in appropriate CMC-Na solution,
Obtain the DT suspensions of 2.0mg/mL.
2.3.4 the preparation of ZG (panax japonicus total saponins) liquid：Precision weighs ZG in right amount, is dissolved in appropriate CMC-Na solution
In, obtain the ZG suspensions of 2.0mg/mL.
2.3.5 the preparation of ZV (panax japonicus saponin V) liquid：Precision weighs ZV in right amount, is dissolved in appropriate CMC-Na solution
In, obtain the ZV suspensions of 1.0mg/mL.
2.3.6 the preparation of DT+ZG (1) liquid：Precision weighs ZG and DT in right amount, is dissolved in appropriate CMC-Na solution, matches somebody with somebody
It is that 1.0mg/mL is suspension (the i.e. DT of 1.0mg/mL with ZG is contained to be made containing DT：ZG=1：1).
2.3.7 the preparation of DT+ZG (2) liquid：Precision weighs ZG and DT in right amount, is dissolved in appropriate CMC-Na solution, matches somebody with somebody
It is that 0.4mg/mL is suspension (the i.e. DT of 1.6mg/mL with ZG is contained to be made containing DT：ZG=1：4).
2.3.8 the preparation of DT+ZG (3) liquid：Precision weighs ZG and DT in right amount, is dissolved in appropriate CMC-Na solution, matches somebody with somebody
It is that 0.3mg/mL is suspension (the i.e. DT of 1.7mg/mL with ZG is contained to be made containing DT：ZG=1：5.6).
2.4 experiment contents.
2.4.1 it is grouped and is administered.
After adaptability is fed 3 days, experimental rat is randomly divided into 9 groups, every group 10, respectively sham-operation group, model group,
Positive group, DT groups, ZG groups, ZV groups, DT+ZG (1) group, DT+ZG (2) group, DT+ZG (3) group.Each group rat gives following controlling respectively
Treat medicine one week：Blank group is normal raising, and any medicine is not given；Positive group gavage benazepil, dosage is 10mg/
kg/day；The medicine of remaining experimental group gavage corresponding dosage.
After each group rat is with 10% chloraldurate 3.0mL/kg intraperitoneal injection of anesthesia, rat RAR is fixed on operation
On platform, the tincture of iodine, 75% alcohol disinfecting field of operation, row left side abdomen otch is used successively to cut skin, muscle and stomach wall each after cropping
Layer, exposes and separates left side ureter, and sham-operation group is only cut abdominal cavity and separates left side ureter, but is not ligatured and cut, its
Its each group rat 4-0 silk threads ligature twice, and the upper point of ligation together is located at left inferior pole of kidney level, and then twice ligation point is cut again
Ureter, layer-by-layer suture puts to death each group animal after postoperative 10 days 10% chloral hydrate anesthesias, take blood, is surveyed by fibronectin
The bright measure fibronectin (FN) of accepted argument.Physiological saline leaves and takes left kidney after lavation repeatedly, raw tissue through 4% poly first
Aldehyde fixer is fixed.Appropriate nephridial tissue is cut, hydroxyproline is determined by the explanation of hydroxyproline kit measurement.
2.4.2 result and analysis.
Routine pathology is checked：First, visually observe：Sham-operation group kidney color is scarlet, and surface is smooth, coating gloss, nothing
Adhesion；Other each group Kidney Volumes increase, and color is pale, shows to be in granular form, and are similar to human body branny kidney, a few regions kidney peplos
Adhesion.2nd, light microscopy checking：Sham-operation group nephron result is clear, and Bowman's capsule is without expansion or inflammatory infiltration.Model control group is big
Piece renal tubular necrosis, kidney region fibrosis hyperplasia, tubular ectasia inside has a large amount of brown color shading materials or necrosis to come off
Epithelial cell, glomerulus number reduce, part glomerulus fibrosis and with bowman's capsule wall adhesion, blister cavities disappear.Administration is each
Group lesion is similar with model control group, but has different degrees of morphology improvement, especially with ZV groups and DT+ZG groups (3) significantly, with
Model control group relatively has notable difference.
Influence of the table 1 to Rats Undergoing Unilateral Urethral Ligation kidney region fibrosis
| Group | Dosage (mg/kg) | Hydroxyproline (μ g/g) | Fibronectin (mg/L) |
| Sham-operation group | - | 393±60 | 6.3±1.8 |
| Model group | - | 786±120 | 27.8±6.2 |
| Positive group | 10 | 537±153 | 17.8±7.3** |
| DT groups | 40 | 686±134 | 21.7±8.9 |
| ZG groups | 40 | 543±121* | 18.5±2.34** |
| ZV groups | 20 | 556±127* | 14.7±5.5** |
| DT+ZG groups (1) | 40 | 715±153 | 25.2±6.3 |
| DT+ZG groups (2) | 40 | 623±148* | 13.7±4.4** |
| DT+ZG groups (3) | 40 | 540±137** | 11.6±3.5* |
Note：* P ＜ 0.05, * * P ＜ 0.01, compare with model group.
T inspections are carried out to each group FN, HYP.Result is as it appears from the above, ZG groups, ZV groups, DT+ZG (2) group, DT+ZG (3) group drops
Low FN, HYP level (comparing with model group, P ＜ 0.05 or P ＜ 0.01).
In sum, panax japonicus polysaccharides, panax japonicus total saponins, the equal energy of panax japonicus saponin V for containing in ring conopsea extraction
Kidney region fibrosis FN, HYP level is enough reduced, suppresses the ring contained in kidney region fibrosis, particularly ring conopsea extraction
Ginseng saponin(e V can have significant effect for suppressing and improving kidney fibrosis, it is seen that ring conopsea extraction can be used to prepare
Anti- kidney fibrosis medicine.
The embodiments described above that the present invention is provided is a part of embodiment of the invention, rather than whole implementation
Example.The detailed description of embodiments of the invention is not intended to limit the scope of claimed invention, but is merely representative of this
The selected embodiment of invention.Based on the embodiment in the present invention, those of ordinary skill in the art are not making creative work
Under the premise of the every other embodiment that is obtained, belong to the scope of protection of the invention.
Claims (10)
1. a kind of ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine, it is characterised in that the panax japonicus is extracted
Thing includes at least one in panax japonicus polysaccharides extract or panax japonicus total saponins extract.
2. ring conopsea extraction according to claim 1 is preparing the application for the treatment of kidney fibrosis medicine, it is characterised in that
The ring conopsea extraction includes that mass ratio is 1：4.5~6 panax japonicus polysaccharides extract and panax japonicus total saponins extract.
3. ring conopsea extraction according to claim 1 is preparing the application for the treatment of kidney fibrosis medicine, it is characterised in that
The ring conopsea extraction includes that mass ratio is 1：5~5.5 panax japonicus polysaccharides extract and panax japonicus total saponins extract.
4. ring conopsea extraction according to claim 1 is preparing the application for the treatment of kidney fibrosis medicine, it is characterised in that
The ring conopsea extraction is the panax japonicus polysaccharides extract, and its per weight consumption is daily 30~450mg/kg.
5. ring conopsea extraction according to claim 1 is preparing the application for the treatment of kidney fibrosis medicine, it is characterised in that：
The ring conopsea extraction is the panax japonicus total saponins extract, and its per weight consumption is daily 40~520mg/kg.
6. ring conopsea extraction according to claim 1 is preparing the application for the treatment of kidney fibrosis medicine, it is characterised in that
The content of panax japonicus saponin V is 50~75% in the panax japonicus total saponins extract.
7. ring conopsea extraction according to claim 1 is preparing the application for the treatment of kidney fibrosis medicine, it is characterised in that
The panax japonicus polysaccharides extract is obtained according to following preparation method：To adding 5~7 times of its quality in panax japonicus powder
Water, immersion is decocted 1~2 hour after 1~3 hour, filtering；2~3 second extractions are carried out to the filter residue after filtering and is filtered；Close
And the filtrate after all filterings, concentrate is concentrated under reduced pressure to give, 2~3 alcohol extractings are carried out to the concentrate；Merge all alcohol extractings
The sediment for obtaining, freeze-drying.
8. ring conopsea extraction according to claim 7 is preparing the application for the treatment of kidney fibrosis medicine, it is characterised in that
The method of the second extraction is：To the water that 3~5 times of its quality is added in the filter residue, then with the speed of 350~450r/min
Rate is stirred and filtered after decocting 1~2 hour.
9. ring conopsea extraction according to claim 1 is preparing the application for the treatment of kidney fibrosis medicine, it is characterised in that
The panax japonicus total saponins extract is obtained according to following preparation method：To adding 9~12 times of its quality in panax japonicus powder
Ethanol, water-bath and refluxing extraction 1~3 hour, filtering after immersion 2~4 hours；2~3 times are carried out to the residue after filtering to carry again
Take and filter, merge the extract solution after all filterings, solid is configured to after ethanol is recovered under reduced pressure：Liquid is 1g：3~5mL's is molten
Liquid, ethanol eluate is obtained using HP-400 macroporous resin columns with water, solution described in the ethanol elution of mass concentration 60% successively,
By the ethanol eluate freeze-drying.
10. a kind of composition, it is characterised in that it include ring conopsea extraction as claimed in any one of claims 1-9 wherein and
Medical accessory.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710231281.5A CN106822205A (en) | 2017-04-11 | 2017-04-11 | Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710231281.5A CN106822205A (en) | 2017-04-11 | 2017-04-11 | Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106822205A true CN106822205A (en) | 2017-06-13 |
Family
ID=59147745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710231281.5A Pending CN106822205A (en) | 2017-04-11 | 2017-04-11 | Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822205A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020244454A1 (en) * | 2019-06-06 | 2020-12-10 | 中国药科大学 | Medical use of pentacyclic triterpenoid saponin compound and pharmaceutical composition thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101978982A (en) * | 2010-11-17 | 2011-02-23 | 石杨 | Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury |
| CN102178716A (en) * | 2011-05-08 | 2011-09-14 | 三峡大学 | Application of rhizoma panacis japonici extract in preparation of chemotherapeutics |
| US20130178436A1 (en) * | 2012-01-10 | 2013-07-11 | Korea Institute Of Science And Technology | Composition for preventing, improving, or treating renal disease including maillard browning reaction products of panax species plant extract |
-
2017
- 2017-04-11 CN CN201710231281.5A patent/CN106822205A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101978982A (en) * | 2010-11-17 | 2011-02-23 | 石杨 | Application of Japanese ginseng or extract thereof to preparation of medicament for resisting gout and repairing hyperuricemic kidney injury |
| CN102178716A (en) * | 2011-05-08 | 2011-09-14 | 三峡大学 | Application of rhizoma panacis japonici extract in preparation of chemotherapeutics |
| US20130178436A1 (en) * | 2012-01-10 | 2013-07-11 | Korea Institute Of Science And Technology | Composition for preventing, improving, or treating renal disease including maillard browning reaction products of panax species plant extract |
Non-Patent Citations (3)
| Title |
|---|
| JYH-FEI LIAO等: "Parmacology of Polysaccharides from Ginseng Species", 《INTERNATIONAL JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES》 * |
| 李艳霞等: "尿胱抑素C在评价高尿酸血症患者早期肾小管功能损害中的临床意义", 《中国老年学杂志》 * |
| 王东等: "人参有效单体对活化的肾系膜细胞株的影响", 《四川中医》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020244454A1 (en) * | 2019-06-06 | 2020-12-10 | 中国药科大学 | Medical use of pentacyclic triterpenoid saponin compound and pharmaceutical composition thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106265754A (en) | A kind of method that a chain of extraction obtains two kinds of effective ingredient from periplaneta americana | |
| CN105031591B (en) | A kind of Chinese medicine composition and preparation method thereof for treating chronic renal failure | |
| CN102160876B (en) | Plant extract composition for preventing and treating arteriosclerosis and preparation method thereof | |
| CN106822205A (en) | Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition | |
| CN102293847B (en) | Chinese medicinal composition for treating constipation, acne and hyperlipidemia, and preparation method | |
| CN101129395A (en) | Traditional Chinese medicine active ingredient composition for treating cardiovascular disease and use thereof | |
| CN106176777A (en) | The new application of rhodioside and be used for treating atherosclerotic compositions | |
| CN107693732B (en) | Medicine composition for treating hypertensive nephropathy and preparation method thereof | |
| CN104324089A (en) | Rhubarb total anthraquinone being stable and uniform in proportion of various components and composition thereof used in jaundice-eliminating treatment of viral hepatitis type B | |
| CN108542926A (en) | The preparation method and pharmaceutical composition of a kind of purslane extract and its application | |
| CN101317881A (en) | Traditional Chinese medicine compound and formulation for removing renal stone | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN100484566C (en) | Chinese medicine preparation for heat-clearing, dampness-removing, diuresis and stone removing and its preparation | |
| CN103251822A (en) | Qi-tonifying and dizziness-relieving Chinese medicine preparation for treating ischemic stroke, coronary disease and angina | |
| CN109172549B (en) | Anti-tumor active composition and application thereof | |
| CN108815448B (en) | Traditional Chinese medicine granules for treating chronic colitis | |
| CN102805836A (en) | Chinese traditional medical composition for treating primary hepatic carcinoma and preparation method thereof | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN113101339A (en) | Decoction for treating chronic liver injury and preparation method and application thereof | |
| CN1178890C (en) | Method for extracting hypericin from Hypericum perforatum and medicine made up using hypericin as main composition | |
| Li et al. | Aqueous extract and polysaccharide of Aconiti Lateralis Radix induce apoptosis and G0/G1 phase cell cycle arrest by PI3K/AKT/mTOR signaling pathway in mesangial cells | |
| CN109893613A (en) | The Chinese native medicine compound prescription pellet and preparation method thereof of therapeutic radiation injury of lungs | |
| CN101176770B (en) | Pharmaceutical composition of folium ginkgo and cattail pollen | |
| CN109512847A (en) | Plumbago zeylanica is in the purposes being used to prepare in treatment pulmonary fibrosis disease drug | |
| CN109125703A (en) | A kind of pharmaceutical composition and preparation method thereof for treating vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170613 |
|
| WD01 | Invention patent application deemed withdrawn after publication |